SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
Authors
Keywords
metabolic dysfunction-associated fatty liver disease, sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, insulin resistance
Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 33, Issue 6, Pages 424-442
Publisher
Elsevier BV
Online
2022-04-29
DOI
10.1016/j.tem.2022.03.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- (2021) Haleh Chehrehgosha et al. Diabetes Therapy
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
- (2021) Lone B Enebo et al. LANCET
- Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
- (2021) Soo Lim et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis
- (2021) Apostolos Tsapas et al. DIABETES OBESITY & METABOLISM
- Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
- (2021) Daniel Ferguson et al. Nature Reviews Endocrinology
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
- (2021) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
- (2020) Mariam Alatrach et al. DIABETES
- Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes
- (2020) Lin Liu et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice
- (2020) Fen Xu et al. INTERNATIONAL JOURNAL OF OBESITY
- Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
- (2020) Eugene Han et al. Journal of Clinical Medicine
- Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs
- (2020) Milton Packer Cardiovascular Diabetology
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
- (2020) Judith Aron-Wisnewsky et al. Nature Reviews Gastroenterology & Hepatology
- SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
- (2020) So Ra Kim et al. Nature Communications
- Evolving role for pharmacotherapy in NAFLD/NASH
- (2020) Suzanna L. Attia et al. CTS-Clinical and Translational Science
- Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis
- (2020) Chrysanthi Mantsiou et al. DIABETES OBESITY & METABOLISM
- SGLT-2 Inhibition and the Endocrine Pancreatic Alpha Cell: Direct or Indirect Mechanisms of Inhibition?
- (2020) Juris J Meier et al. ENDOCRINOLOGY
- From NAFLD to MAFLD: Implications of a premature change in terminology
- (2020) Zobair M Younossi et al. HEPATOLOGY
- The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet
- (2020) Emmanuel Somm et al. Translational Research
- Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2020) Hoda Taheri et al. ADVANCES IN THERAPY
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
- (2020) Mohammad S. Kuchay et al. DIABETOLOGIA
- SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology
- (2020) Norio Akuta et al. INTERNAL MEDICINE
- MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
- (2020) Sakura Yamamura et al. LIVER INTERNATIONAL
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
- (2020) Mikkel Breinholt Kjær et al. Expert Review of Gastroenterology & Hepatology
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
- (2020) Michael A. Nauck et al. Molecular Metabolism
- MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
- (2020) Ying-Xin Xian et al. CHINESE MEDICAL JOURNAL
- Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial
- (2020) Wen Guo et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
- (2020) Brent A McLean et al. ENDOCRINE REVIEWS
- Clinical utility of the MAFLD definition
- (2020) Kenneth I. Zheng et al. JOURNAL OF HEPATOLOGY
- Non-alcoholic fatty liver disease: Not time for an obituary just yet!
- (2020) Shivaram Prasad Singh et al. JOURNAL OF HEPATOLOGY
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
- (2020) David C Wheeler et al. Lancet Diabetes & Endocrinology
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mitochondrial Dysfunction in Type 2 Diabetes Mellitus: An Organ-Based Analysis
- (2019) Mark V Pinti et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
- (2019) Joan Khoo et al. LIVER INTERNATIONAL
- Autophagy in liver diseases: Time for translation?
- (2019) Manon Allaire et al. JOURNAL OF HEPATOLOGY
- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
- (2019) Peter J. Eddowes et al. GASTROENTEROLOGY
- Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
- (2019) Lee-Lee Lai et al. DIGESTIVE DISEASES AND SCIENCES
- Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study
- (2019) Angelo Maria Patti et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
- (2019) Aino Latva-Rasku et al. DIABETES CARE
- Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)
- (2019) Masaya Koshizaka et al. DIABETES OBESITY & METABOLISM
- Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
- (2019) Yeonhee Hong et al. Journal of Cachexia Sarcopenia and Muscle
- Glucagon Receptor Signaling and Lipid Metabolism
- (2019) Katrine D. Galsgaard et al. Frontiers in Physiology
- Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
- (2019) Philip Newsome et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Liraglutide treatment reduced interleukin 6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy
- (2019) C. Brock et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
- (2019) Srilaxmi Kalavalapalli et al. JOURNAL OF ENDOCRINOLOGY
- Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial
- (2019) Christian Anholm et al. ATHEROSCLEROSIS
- Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
- (2019) Sabine Kahl et al. DIABETES CARE
- Glucagon-like peptide 1 (GLP-1)
- (2019) T.D. Müller et al. Molecular Metabolism
- The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus
- (2019) Weiling Leng et al. Annals of Translational Medicine
- Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways
- (2019) Joseph Yi Zhou et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
- (2019) Mette Simone Aae Madsen et al. Scientific Reports
- Energy restriction in obese women suggest linear reduction of hepatic fat content and time-dependent metabolic improvements
- (2019) Hans-Erik Johansson et al. Nutrition & Diabetes
- Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
- (2019) Amalia Gastaldelli et al. DIABETES OBESITY & METABOLISM
- Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy
- (2019) Xinyang Yu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
- (2019) Golnaz Ranjbar et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors
- (2018) Soo Lim et al. ATHEROSCLEROSIS
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin
- (2018) David Polidori et al. DIABETES OBESITY & METABOLISM
- Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
- (2018) K. Cusi et al. DIABETIC MEDICINE
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns
- (2018) Soo Lim et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway
- (2018) Ning Shao et al. Gastroenterology Research and Practice
- Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
- (2018) Takashi Sasaki et al. Journal of Diabetes Investigation
- Effects of liraglutide, metformin, and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial
- (2018) Wen-Huan Feng et al. Journal of Diabetes Investigation
- Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2018) Masanori Shimizu et al. DIABETES OBESITY & METABOLISM
- Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)
- (2018) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- Liraglutide modulates gut microbiota and reduces NAFLD in obese mice
- (2018) GV Moreira et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- Hepatocyte-Macrophage Acetoacetate Shuttle Protects against Tissue Fibrosis
- (2018) Patrycja Puchalska et al. Cell Metabolism
- Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
- (2018) Kenneth Cusi et al. DIABETES OBESITY & METABOLISM
- Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk
- (2018) Jin Hee Kim et al. DIABETES OBESITY & METABOLISM
- Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD
- (2018) Jinhua Yan et al. HEPATOLOGY
- Impact of SGLT2 inhibitor to histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus
- (2018) Norio Akuta et al. HEPATOLOGY RESEARCH
- Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
- (2018) Soo Lim et al. Obesity Reviews
- Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
- (2018) Mitsuko Inoue et al. Journal of Diabetes Investigation
- Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
- (2017) Akio Ohta et al. EXPERT OPINION ON PHARMACOTHERAPY
- Liraglutide causes large and rapid epicardial fat reduction
- (2017) Gianluca Iacobellis et al. Obesity
- Effects of Bariatric Surgery on Non-alcoholic Fatty Liver Disease: Magnetic Resonance Imaging Is an Effective, Non-invasive Method to Evaluate Changes in the Liver Fat Fraction
- (2017) Dennis M. Hedderich et al. OBESITY SURGERY
- How bariatric surgery affects liver volume and fat density in NAFLD patients
- (2017) Ran B. Luo et al. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
- Soluble Uric Acid Activates the NLRP3 Inflammasome
- (2017) Tarcio Teodoro Braga et al. Scientific Reports
- β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares
- (2017) Emily L. Goldberg et al. Cell Reports
- Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
- (2017) Wenhuan Feng et al. Journal of Diabetes
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies
- (2017) Fernanda Cristina de Mesquita et al. Scientific Reports
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
- (2016) A. Dutour et al. DIABETES OBESITY & METABOLISM
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
- (2016) Mark M. Smits et al. DIABETOLOGIA
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) et al. DIABETOLOGIA
- Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
- (2016) Amalia Gastaldelli et al. HEPATOLOGY
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin
- (2016) Anna Vanderheiden et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease
- (2016) Anders E. Junker et al. JOURNAL OF HEPATOLOGY
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
- (2016) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- The role of the gut microbiota in NAFLD
- (2016) Christopher Leung et al. Nature Reviews Gastroenterology & Hepatology
- Sirtuins and nonalcoholic fatty liver disease
- (2016) Fatiha Nassir et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
- (2016) Teruo Jojima et al. Diabetology & Metabolic Syndrome
- Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes
- (2016) Xin Liao et al. Scientific Reports
- The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
- (2016) Michael A Nauck et al. Lancet Diabetes & Endocrinology
- The Gut Microbiota from Lean and Obese Subjects Contribute Differently to the Fermentation of Arabinogalactan and Inulin
- (2016) Marisol Aguirre et al. PLoS One
- Exendin-4 regulates redox homeostasis in rats fed with high-fat diet
- (2015) Shiwei Niu et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
- (2015) An Tang et al. DIABETES CARE
- Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes
- (2015) Dongmei Li et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease
- (2015) Yun-Hee Youm et al. NATURE MEDICINE
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes
- (2014) Yan Bi et al. ACTA DIABETOLOGICA
- SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
- (2014) Yukihiro Chino et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)
- (2014) Yuichiro Eguchi et al. HEPATOLOGY RESEARCH
- Exendin-4, a glucagon-like peptide-1 receptor agonist, modulates hepatic fatty acid composition and Δ-5-desaturase index in a murine model of non-alcoholic steatohepatitis
- (2014) TAKUMI KAWAGUCHI et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia
- (2014) David G. Cotter et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations
- (2014) Victor de Lédinghen et al. JOURNAL OF HEPATOLOGY
- The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors
- (2014) John P.H. Wilding METABOLISM-CLINICAL AND EXPERIMENTAL
- Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective
- (2014) Aaron M. Gusdon et al. Oxidative Medicine and Cellular Longevity
- Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease
- (2014) Christine Bernsmeier et al. PLoS One
- Obesity, fatty liver disease and intestinal microbiota
- (2014) Nur Arslan WORLD JOURNAL OF GASTROENTEROLOGY
- Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
- (2014) Lise L Gluud et al. BMJ Open
- Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways
- (2013) Makoto Nishizawa et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Hydrogen Sulfide Signaling in the Gastrointestinal Tract
- (2013) David R. Linden ANTIOXIDANTS & REDOX SIGNALING
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
- (2013) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Neuroprotective Effects of Liraglutide for Stroke Model of Rats
- (2013) Kenichiro Sato et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Direct effect of GLP-1 infusion on endogenous glucose production in humans
- (2012) M. Seghieri et al. DIABETOLOGIA
- Uric Acid Induces Hepatic Steatosis by Generation of Mitochondrial Oxidative Stress
- (2012) Miguel A. Lanaspa et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging
- (2012) Arian Mashhood et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- Functional interactions between the gut microbiota and host metabolism
- (2012) Valentina Tremaroli et al. NATURE
- Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- (2012) Daniel J. Cuthbertson et al. PLoS One
- GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice
- (2012) Edwin T. Parlevliet et al. PLoS One
- Suppression of Oxidative Stress by -Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
- (2012) T. Shimazu et al. SCIENCE
- Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction
- (2011) Jeffrey D Browning et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort
- (2011) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
- (2011) Shvetank Sharma et al. PLoS One
- Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
- (2010) Shani Ben-Shlomo et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Hepatocyte-Specific Deletion of SIRT1 Alters Fatty Acid Metabolism and Results in Hepatic Steatosis and Inflammation
- (2009) Aparna Purushotham et al. Cell Metabolism
- The Glucagon-Like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of Its Incretin Action
- (2008) Julio E. Ayala et al. ENDOCRINOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search